Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Fampridine (Fampyra®) is recommended as an option for use within NHS Wales for the improvement of walking in adult patients with multiple sclerosis with walking disability (Expanded Disability Status Scale [EDSS] 4 to 7). This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | fampridine (Fampyra®) | ||
| Formulation | 10 mg prolonged-release tablet | ||
| Reference number | 3942 | ||
| Indication | Improvement of walking in adult patients with multiple sclerosis with walking disability (Expanded Disability Status Scale 4–7) |
||
| Company | Biogen Idec Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 1919 | ||
| NMG meeting date | 06/11/2019 | ||
| AWMSG meeting date | 11/12/2019 | ||
| Date of issue | 12/12/2019 | ||
| Commercial arrangement | WPAS | ||